Research programme: pain therapeutics - Biogen

Drug Profile

Research programme: pain therapeutics - Biogen

Alternative Names: ASK1 modulators; GPR84 modulators; mPGES modulators; P2Y14 modulators

Latest Information Update: 24 Jun 2015

Price : $50

At a glance

  • Originator Convergence Pharmaceuticals
  • Developer Biogen
  • Class Analgesics
  • Mechanism of Action GPR84 protein modulators; MAP-kinase-activated kinase 5 modulators; P2RY14 protein modulators; Prostaglandin-E synthase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Pain

Most Recent Events

  • 13 Jan 2014 Research programme: pain therapeutics - Convergence Pharmaceuticals is available for licensing as of 01 Jan 2014. http://www.convergencepharma.com
  • 01 Jan 2014 Early research in Pain in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top